HIV VACCINES AND MICROBICIDES RESOURCE TRACKING WORKING GROUP

Press Release: Investment in post-efficacy R&D critical for PrEP, other new HIV prevention options: New funding sources needed to sustain innovative HIV prevention R&D 

Download the report: HIV Prevention Research & Development Funding Trends, 2000-2014

Investing in innovation in an evolving global health and development landscape

In 2014, the reported funding for HIV prevention R&D decreased by US$10 million from the previous year to a total of US$1.25 billion (Figure 2). While investments toward research in preventive vaccines, PrEP, female condoms and prevention of vertical transmission increased in 2014, investments towards microbicides, treatment as prevention and medical male circumcision decreased (Figure 3). Overall funding has remained at nearly the same level for approximately a decade. As in past years, the public sector made up the majority of total funding at US$990 million (79 percent) (Figure 4), with the US public sector contributing US$868 million (69 percent). European public-sector funding made up US$69 million (five percent), public-sector investment from other countries made up US$52 million (four percent), philanthropic investment was US$200 million (16 percent) and investment from the commercial sector was US$63 million (five percent).

All Content © 2000 - 2015 HIV Resource Tracking. Website Maintained by Progress Technology, Inc.
Log In / Administration